CV Death Lower Among Patients Undergoing TEER vs. Mitral Valve Surgery

When comparing long-term outcomes of transcatheter edge-to-edge repair (TEER) vs. isolated mitral valve repair surgery, cardiovascular death was lower among patients undergoing TEER, according to new research presented at ESC Congress 2023.

The three-pronged nationwide trial out of France compared long-term outcomes of TEER vs isolated mitral valve surgery, TEER vs. mitral valve repair, and TEER vs. isolated mitral valve surgery in patients with primary and secondary mitral regurgitation (MR). A total of 598,036 patients with MR and seen in French hospitals between 2012 and 2022 made up the study. Of these patients, 57,140 were treated with isolated mitral valve surgery or TEER.

"The trial is the largest propensity matched comparison of mitral TEER vs. isolated mitral valve surgery for patients with severe MR," said Pierre Deharo, MD, PhD, when presenting the findings. He noted that in the matched cohort of patients, TEER was associated with lower rates of cardiovascular death, pulmonary edema, atrial fibrillation, pacemaker implantation, stroke, major bleeding and endocarditis. A significant interaction between age >75 years and ≥4 and reduced cardiovascular and all-cause mortality was also observed in the TEER group.

When looking at TEER vs. surgery in patients with primary or secondary MR, TEER was associated with lower incidences of cardiovascular death compared with isolated surgery when treating secondary MR. However, the difference between TEER and surgery when treating primary MR did not reach significance, he said.

Clinical Topics: Valvular Heart Disease

Keywords: ESC Congress, ESC23, ACC International

< Back to Listings